PMV Pharmaceuticals develops oral small molecule cancer drugs that target mutations in the p53 protein. PMVP reports earnings on Wed, Nov 11, 2026.
Earnings
Earnings calendar →Analyst Ratings & Price Targets
Analyst Ratings →| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| Sep 4 | HC Wainwright & Co. | Reiterated | Buy | |
| Jul 8 | Ladenburg Thalmann | Assumed coverage | Buy |
Seasonality
How PMVP has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2020.
Whale Options Flow
90DNo whale options trades in PMVP in the last 90 days.
AI Auto Pilots
Paper tradingStreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether PMVP is in one of them and how their past PMVP trades turned out.
Macro & Market News
All StreetAlpha news →StreetAlpha hasn't covered PMVP in an article yet. Here's the latest on the wider market.
About PMV Pharmaceuticals
PMV Pharmaceuticals is a cancer drug developer based in Princeton, New Jersey. It develops oral small molecule medicines that aim to restore normal function to mutant p53, a protein that helps stop cancer growth when it works properly. Its lead product candidate, rezatapopt, targets a specific p53 mutation found in several solid tumors, including some ovarian, lung and colorectal cancers. The company's therapies are intended for cancer patients whose tumors carry these mutations.
- Headquarters
- Princeton, NJ